Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Cardiovasc Ther ; 30(3): 136-44, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21106034

RESUMO

AIMS: The goal of this study was to investigate the importance of the vascular angiotensin convertase enzyme (ACE) in coronary artery bypass graft surgery (CABG) patients. METHODS: Vascular tissue (distal saphenous vein [n= 163] and/or radial artery [n= 120] segments) and blood samples were collected from CABG patients (n= 81). We studied (i) the potency of angiotensin I (AngI) and angiotensin II (AngII) to evoke vascular contractions; (ii) vascular and plasma ACE concentrations; and (iii) ACE genotype of the patients enrolled. RESULTS: The ratio of the potencies (EC(50) ) of AngII and AngI was significantly lower in radial artery compared to the saphenous vein (0.17 ± 0.03 nM and 0.51 ± 0.14 nM, respectively, P= 0.003), suggesting a 3-fold more effective AngI conversion in saphenous vein samples. Angiotensin constrictions were inhibited with telmisartan and captopril in both saphenous veins and radial arteries. Vascular ACE expression was significantly higher in saphenous vein compared to radial artery (9.7 ± 1.0 ng/mg and 5.3 ± 0.7 ng/mg, respectively, P= 0.01). Serum but no tissue ACE concentration was determined by ACE insertion/deletion polymorphism. Accordingly, no relation was found between serum and tissue ACE expression. CONCLUSION: ACE-inhibitor therapy targeting tissue located ACE may be beneficial to patients with saphenous vein grafts after CABG surgery.


Assuntos
Ponte de Artéria Coronária/efeitos adversos , Peptidil Dipeptidase A/metabolismo , Complicações Pós-Operatórias/etiologia , Veia Safena/transplante , Idoso , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Relação Dose-Resposta a Droga , Feminino , Humanos , Hungria , Masculino , Pessoa de Meia-Idade , Peptidil Dipeptidase A/sangue , Peptidil Dipeptidase A/genética , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/enzimologia , Estudos Prospectivos , Artéria Radial/efeitos dos fármacos , Artéria Radial/enzimologia , Medição de Risco , Fatores de Risco , Veia Safena/efeitos dos fármacos , Veia Safena/enzimologia , Fatores de Tempo , Resultado do Tratamento , Vasoconstritores/farmacologia
2.
Arterioscler Thromb Vasc Biol ; 30(7): 1347-53, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20378845

RESUMO

OBJECTIVE: We investigated whether red cell infiltration of atheromatous lesions promotes the later stages of atherosclerosis. METHODS AND RESULTS: We find that oxidation of ferro (FeII) hemoglobin in ruptured advanced lesions occurs generating ferri (FeIII) hemoglobin and via more extensive oxidation ferrylhemoglobin (FeIII/FeIV=O). The protein oxidation marker dityrosine accumulates in complicated lesions, accompanied by the formation of cross-linked hemoglobin, a hallmark of ferrylhemoglobin. Exposure of normal red cells to lipids derived from atheromatous lesions causes hemolysis and oxidation of liberated hemoglobin. In the interactions between hemoglobin and atheroma lipids, hemoglobin and heme promote further lipid oxidation and subsequently endothelial reactions such as upregulation of heme oxygenase-1 and cytotoxicity to endothelium. Oxidative scission of heme leads to release of iron and a feed-forward process of iron-driven plaque lipid oxidation. The inhibition of heme release from globin by haptoglobin and sequestration of heme by hemopexin suppress hemoglobin-mediated oxidation of lipids of atheromatous lesions and attenuate endothelial cytotoxicity. CONCLUSIONS: The interior of advanced atheromatous lesions is a prooxidant environment in which erythrocytes lyse, hemoglobin is oxidized to ferri- and ferrylhemoglobin, and released heme and iron promote further oxidation of lipids. These events amplify the endothelial cell cytotoxicity of plaque components.


Assuntos
Aorta/metabolismo , Aterosclerose/sangue , Eritrócitos/metabolismo , Hematoma/sangue , Heme/metabolismo , Hemoglobinas/metabolismo , Ferro/sangue , Aorta/patologia , Aterosclerose/patologia , Sobrevivência Celular , Células Cultivadas , Células Endoteliais/metabolismo , Células Endoteliais/patologia , Glutationa/metabolismo , Glutationa Peroxidase/metabolismo , Haptoglobinas/metabolismo , Hematoma/patologia , Heme Oxigenase-1/sangue , Hemólise , Hemopexina/metabolismo , Humanos , Peroxidação de Lipídeos , Lipoproteínas LDL/metabolismo , Metemoglobina/metabolismo , Oxirredução , Estresse Oxidativo , Tirosina/análogos & derivados , Tirosina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA